Jordan

Jordan

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
3.37 (3.26 - 3.48) 2019 Modelled IHME
3.41 (3.30 - 3.51) 2018 Modelled IHME
3.48 (3.36 - 3.59) 2017 Modelled IHME
3.61 (3.50 - 3.71) 2016 Modelled IHME
3.77 (3.65 - 3.89) 2015 Modelled IHME
3.92 (3.81 - 4.04) 2014 Modelled IHME
4.07 (3.96 - 4.20) 2013 Modelled IHME
4.23 (4.11 - 4.35) 2012 Modelled IHME
4.39 (4.26 - 4.52) 2011 Modelled IHME
4.57 (4.43 - 4.71) 2010 Modelled IHME
4.78 (4.63 - 4.92) 2009 Modelled IHME
5 (4.85 - 5.14) 2008 Modelled IHME
5.24 (5.08 - 5.38) 2007 Modelled IHME
5.48 (5.31 - 5.63) 2006 Modelled IHME
5.72 (5.54 - 5.88) 2005 Modelled IHME
5.95 (5.77 - 6.11) 2004 Modelled IHME
6.18 (6.01 - 6.34) 2003 Modelled IHME
6.42 (6.23 - 6.58) 2002 Modelled IHME
6.66 (6.47 - 6.83) 2001 Modelled IHME
6.9 (6.68 - 7.08) 2000 Modelled IHME
7.16 (6.94 - 7.35) 1999 Modelled IHME
7.44 (7.19 - 7.63) 1998 Modelled IHME
7.71 (7.44 - 7.91) 1997 Modelled IHME
7.97 (7.67 - 8.19) 1996 Modelled IHME
8.2 (7.85 - 8.43) 1995 Modelled IHME
8.4 (8.07 - 8.62) 1994 Modelled IHME
8.58 (8.27 - 8.81) 1993 Modelled IHME
8.76 (8.44 - 8.99) 1992 Modelled IHME
8.91 (8.58 - 9.14) 1991 Modelled IHME
9.04 (8.72 - 9.28) 1990 Modelled IHME
2.59 (1.64 - 3.86) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.53 (0.50 - 0.56) 2019 Modelled IHME
0.57 (0.54 - 0.61) 2018 Modelled IHME
0.59 (0.55 - 0.63) 2017 Modelled IHME
0.59 (0.55 - 0.62) 2016 Modelled IHME
0.58 (0.54 - 0.62) 2015 Modelled IHME
0.54 (0.51 - 0.58) 2014 Modelled IHME
0.48 (0.45 - 0.51) 2013 Modelled IHME
0.41 (0.39 - 0.44) 2012 Modelled IHME
0.35 (0.33 - 0.38) 2011 Modelled IHME
0.33 (0.31 - 0.35) 2010 Modelled IHME
0.33 (0.31 - 0.35) 2009 Modelled IHME
0.33 (0.31 - 0.35) 2008 Modelled IHME
0.33 (0.31 - 0.35) 2007 Modelled IHME
0.33 (0.31 - 0.35) 2006 Modelled IHME
0.33 (0.31 - 0.36) 2005 Modelled IHME
0.34 (0.32 - 0.36) 2004 Modelled IHME
0.36 (0.34 - 0.38) 2003 Modelled IHME
0.39 (0.37 - 0.41) 2002 Modelled IHME
0.43 (0.40 - 0.45) 2001 Modelled IHME
0.48 (0.45 - 0.51) 2000 Modelled IHME
0.81 (0.76 - 0.86) 1999 Modelled IHME
1.56 (1.45 - 1.66) 1998 Modelled IHME
2.48 (2.31 - 2.66) 1997 Modelled IHME
3.37 (3.12 - 3.62) 1996 Modelled IHME
4 (3.70 - 4.31) 1995 Modelled IHME
4.41 (4.09 - 4.74) 1994 Modelled IHME
4.78 (4.46 - 5.13) 1993 Modelled IHME
5.1 (4.77 - 5.49) 1992 Modelled IHME
5.34 (5 - 5.76) 1991 Modelled IHME
5.49 (5.15 - 5.93) 1990 Modelled IHME
1.01 (0.55 - 1.73) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
37 (29 - 47) 2019 Modelled IHME
37 (29 - 47) 2018 Modelled IHME
37 (29 - 47) 2017 Modelled IHME
37 (28 - 47) 2016 Modelled IHME
36 (28 - 47) 2015 Modelled IHME
36 (28 - 47) 2014 Modelled IHME
36 (28 - 47) 2013 Modelled IHME
36 (28 - 47) 2012 Modelled IHME
36 (28 - 47) 2011 Modelled IHME
36 (28 - 47) 2010 Modelled IHME
36 (28 - 47) 2009 Modelled IHME
37 (28 - 47) 2008 Modelled IHME
37 (29 - 48) 2007 Modelled IHME
37 (29 - 48) 2006 Modelled IHME
37 (29 - 48) 2005 Modelled IHME
38 (29 - 48) 2004 Modelled IHME
38 (30 - 48) 2003 Modelled IHME
38 (30 - 48) 2002 Modelled IHME
38 (30 - 49) 2001 Modelled IHME
39 (31 - 49) 2000 Modelled IHME
39 (31 - 49) 1999 Modelled IHME
39 (31 - 49) 1998 Modelled IHME
39 (31 - 49) 1997 Modelled IHME
40 (31 - 50) 1996 Modelled IHME
40 (31 - 50) 1995 Modelled IHME
40 (32 - 50) 1994 Modelled IHME
40 (31 - 50) 1993 Modelled IHME
40 (31 - 50) 1992 Modelled IHME
40 (31 - 50) 1991 Modelled IHME
40 (31 - 49) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
96 2018 Survey/reported WHO/UNICEF
99 2017 Survey/reported WHO/UNICEF
98 2016 Survey/reported WHO/UNICEF
99 2015 Survey/reported WHO/UNICEF
98 2014 Survey/reported WHO/UNICEF
98 2013 Survey/reported WHO/UNICEF
98 2012 Survey/reported WHO/UNICEF
98 2011 Survey/reported WHO/UNICEF
98 2010 Survey/reported WHO/UNICEF
98 2009 Survey/reported WHO/UNICEF
97 2008 Survey/reported WHO/UNICEF
98 2007 Survey/reported WHO/UNICEF
98 2006 Survey/reported WHO/UNICEF
95 2005 Survey/reported WHO/UNICEF
95 2004 Survey/reported WHO/UNICEF
97 2003 Survey/reported WHO/UNICEF
95 2002 Survey/reported WHO/UNICEF
97 2001 Survey/reported WHO/UNICEF
93 2000 Survey/reported WHO/UNICEF
92 1999 Survey/reported WHO/UNICEF
91 1998 Survey/reported WHO/UNICEF
90 1997 Survey/reported WHO/UNICEF
85 1996 Survey/reported WHO/UNICEF
54 1995 Survey/reported WHO/UNICEF
Showing out of
Show more

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2018
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
No
OST in at least one prison
No
NSP in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
0.96 (0.78 - 1.19) 2019 Modelled IHME
0.85 (0.69 - 1.04) 2018 Modelled IHME
0.75 (0.61 - 0.92) 2017 Modelled IHME
0.65 (0.53 - 0.80) 2016 Modelled IHME
0.59 (0.48 - 0.74) 2015 Modelled IHME
0.59 (0.48 - 0.73) 2014 Modelled IHME
0.59 (0.48 - 0.74) 2013 Modelled IHME
0.59 (0.48 - 0.73) 2012 Modelled IHME
0.59 (0.48 - 0.74) 2011 Modelled IHME
0.6 (0.48 - 0.74) 2010 Modelled IHME
0.6 (0.48 - 0.74) 2009 Modelled IHME
0.6 (0.48 - 0.75) 2008 Modelled IHME
0.61 (0.49 - 0.76) 2007 Modelled IHME
0.63 (0.50 - 0.77) 2006 Modelled IHME
0.64 (0.51 - 0.79) 2005 Modelled IHME
0.69 (0.55 - 0.86) 2004 Modelled IHME
0.77 (0.62 - 0.96) 2003 Modelled IHME
0.87 (0.70 - 1.08) 2002 Modelled IHME
0.95 (0.77 - 1.17) 2001 Modelled IHME
0.98 (0.79 - 1.21) 2000 Modelled IHME
0.98 (0.79 - 1.21) 1999 Modelled IHME
0.98 (0.79 - 1.21) 1998 Modelled IHME
0.97 (0.78 - 1.21) 1997 Modelled IHME
0.97 (0.78 - 1.21) 1996 Modelled IHME
0.97 (0.77 - 1.20) 1995 Modelled IHME
0.97 (0.78 - 1.20) 1994 Modelled IHME
0.97 (0.78 - 1.20) 1993 Modelled IHME
0.97 (0.78 - 1.20) 1992 Modelled IHME
0.97 (0.78 - 1.20) 1991 Modelled IHME
0.98 (0.78 - 1.21) 1990 Modelled IHME
Showing out of
Show more

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
32 (23 - 41) 2019 Modelled IHME
32 (23 - 41) 2018 Modelled IHME
32 (23 - 41) 2017 Modelled IHME
32 (23 - 41) 2016 Modelled IHME
32 (23 - 41) 2015 Modelled IHME
32 (23 - 41) 2014 Modelled IHME
32 (23 - 41) 2013 Modelled IHME
33 (23 - 41) 2012 Modelled IHME
33 (23 - 41) 2011 Modelled IHME
33 (23 - 41) 2010 Modelled IHME
33 (23 - 42) 2009 Modelled IHME
32 (23 - 41) 2008 Modelled IHME
32 (23 - 41) 2007 Modelled IHME
32 (23 - 42) 2006 Modelled IHME
33 (23 - 42) 2005 Modelled IHME
32 (23 - 41) 2004 Modelled IHME
32 (23 - 41) 2003 Modelled IHME
32 (23 - 41) 2002 Modelled IHME
32 (23 - 41) 2001 Modelled IHME
32 (23 - 40) 2000 Modelled IHME
32 (23 - 40) 1999 Modelled IHME
32 (22 - 40) 1998 Modelled IHME
32 (22 - 40) 1997 Modelled IHME
31 (22 - 40) 1996 Modelled IHME
31 (22 - 40) 1995 Modelled IHME
31 (22 - 40) 1994 Modelled IHME
31 (22 - 40) 1993 Modelled IHME
31 (22 - 40) 1992 Modelled IHME
32 (22 - 40) 1991 Modelled IHME
32 (23 - 40) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
0 2016 Survey/reported Harm Reduction International, 2018
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
No
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
No
OST in at least one prison
No
NSP in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
3.37 (%)
2019
(3.26 - 3.48(%))
IHME
HCV (RNA/cAg+)
0.96 (%)
2019
(0.78 - 1.19(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
166
2019
(121 - 217)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
333
2019
(255 - 425)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.53 (%)
2019, latest modelled
(0.50 - 0.56(%))
IHME

Prevalence PWID

No data available

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines